Loading
Apimeds Pharmaceuticals US, Inc. Stock: price and insider trades · United States
US·Mcap US$6.4M
No insider purchase over the last 90 days. The latest, by Kim Christopher, was filed 15 May 2025.
Apimeds Pharmaceuticals US, Inc.: what insiders have been doing
This page follows insider dealings at Apimeds Pharmaceuticals US, Inc. as filed with SEC (Form 4). Nothing new has been filed by managers of Apimeds Pharmaceuticals US, Inc. in twelve months, the latest record being from 11 June 2025.
In the same market, recent insider purchases at Relmada Therapeutics, Inc. and Uber Technologies, Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
6
Thresholds
n/a
Buy Volume
€2M
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleChristopher Kim1 buy
Inscobee Inc.1 buy
Jakap Koo1 buy
Since the insiders bought
- -12.4%Entry US$17.00 · Close at T+365 US$14.90
- -12.7%Entry US$17.30 · Close at T+365 US$15.10
- -12.7%Entry US$17.30 · Close at T+365 US$15.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.24
Analyst consensus
Income statement
EBITDA-US$5.7M
Net income-US$6M0.0% margin
Valuation
P/Book6.5x
Balance sheet & cash
Market capUS$6.4M
Total debtUS$7.8M
Free Cash Flow-US$9M
Profitability & ownership
% insiders58.7%
% institutions3.0%
Last declaration on 11 June 2025
Declarations6 total
71,090 shares@ US$2.608.5% of flowCommon Stock, par value $0.01 per shareSEC:0001474506-25-000109:0
750,000 shares0Common Stock, par value $0.01 per shareSEC:0001474506-25-000099:0
250,000 shares0Common Stock, par value $0.01 per shareSEC:0001474506-25-000100:0
19,770 shares@ US$1.82100.0% of flowCommon Stock, par value $0.01 per shareSEC:0001474506-25-000096:0
Canonical exit: 11 Aug 2025 (T+90)
500,000 shares@ US$4.0091.5% of flowCommon Stock, par value $0.01 per shareSEC:0001474506-25-000089:0
Canonical exit: 10 Aug 2025 (T+90)
6 of 6 declarations
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. is a company focused on developing innovative treatments for rare diseases. It is listed on the XNAS market.
